Pfizer Inc.’s $43 billion takeover of Seagen Inc. was unconditionally approved by European Union regulators, after they found the deal wouldn’t hamper competition for cancer treatments.
The European Commission said Thursday the deal was unlikely to have a negative impact on prices, and that no concessions were required for the watchdog to approve the deal.
Pfizer announced in March that it would acquire the Washington-based cancer-drug maker as a way to move out of pandemic mode. Seagen is a leader in developing a type of medicine called antibody-drug conjugates, which use antibodies to deposit a strong concentration of drug ...
